Breaking Finance News

Leerink Partners disclosed EXACT Sciences (NASDAQ:EXAS), hiking its price target to $50.00 earlier today

Reporting a potential upside of 0.15%, Leerink Partners upped the price target of EXACT Sciences (NASDAQ:EXAS) to $50.00

On 07/26/2017, Canaccord released a statement on EXACT Sciences (NASDAQ:EXAS) upped the target price from $42.00 to $45.00 that suggested an upside of 0.21%.

Having a price of $43.40, EXACT Sciences (NASDAQ:EXAS) traded 3.69% higher on the day. With the last close up 36.60% from the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.04% over the same period. EXAS has recorded a 50-day average of $40.21 and a two hundred day average of $32.94. Trade Volume was down over the average, with 942,130 shares of EXAS changing hands under the typical 1,724,700

Recent Performance Chart

EXACT Sciences (NASDAQ:EXAS)

EXACT Sciences has with a one year low of $13.05 and a one year high of $45.18 and has a market capitalization of $0.

A total of 10 analysts have released a report on EXACT Sciences. Five analysts rating the company a strong buy, one analyst rating the company a buy, seven analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $8.55.

General Company Details For EXACT Sciences (NASDAQ:EXAS)

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Cologuard test is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It focuses on the development of additional tests for other types of cancer. It is developing a blood-based biomarker test to aid in the early detection of lung cancer in individuals with lung nodules discovered through a computerized tomography (CT) or other scan.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.